Gland Pharma Limited
Gland Pharma Limited (GLAND.NS) Stock Overview
Explore Gland Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
304.6B
P/E Ratio
35.95
EPS (TTM)
$51.37
ROE
0.09%
GLAND.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Gland Pharma Limited (GLAND.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 56.99, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1421.52.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 35.95 and a market capitalization of 304.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.